DSI Seaford is a medicare approved dialysis facility center in Seaford, Delaware and it has 16 dialysis stations. It is located in Sussex county at 600 Health Services Drive, Seaford, DE, 19973. You can reach out to the office of DSI Seaford at (302) 262-0852. This dialysis clinic is managed and/or owned by Us Renal Care, Inc.. DSI Seaford has the following ownership type - Profit. It was first certified by medicare in August, 2009. The medicare id for this facility is 082518 and it accepts patients under medicare ESRD program.
| Name | DSI Seaford |
|---|---|
| Location | 600 Health Services Drive, Seaford, Delaware |
| No. of Dialysis Stations | 16 |
| Medicare ID | 082518 |
| Managed By | Us Renal Care, Inc. |
| Ownership Type | Profit |
| Late Shifts | No |
| 600 Health Services Drive, Seaford, Delaware, 19973 | |
| (302) 262-0852 | |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
| NPI Number | 1578729984 |
| Organization Name | U.s. Renal Care Seaford Dialysis |
| Doing Business As | Ldsd Llc |
| Address | 600 Health Services Dr Seaford, Delaware, 19973 |
| Phone Number | (302) 262-0852 |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 73% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 15% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 60% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 15% | 14% |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 59% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 19% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 22% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 69% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 12% |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 80% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 20% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 68% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 8% | 12% |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 65 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 9 |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 69 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 643 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
| Adult patients getting regular peritoneal dialysis at the center | 27 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 234 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 94 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at DSI Seaford with elevated calcium levels.
| Patients with hypercalcemia | 93 |
| Hypercalcemia patient months | 883 |
| Patients with Serumphosphor | 96 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 31 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 13 |
| Patients with Serumphosphor greater than 7 mg/dL | 8 |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 68 |
| Patient months included in arterial venous fistula and catheter summaries | 627 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 61 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 12 |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 90 |
| Hospitalization Rate in facility | 112.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 213.7 |
| Hospitalization Rate: Lower Confidence Limit | 65.1 |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at DSI Seaford were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 17 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 27.7 |
| Readmission Rate: Lower Confidence Limit | 9.1 |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at DSI Seaford get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.8 (As Expected) |
| SIR: Upper Confidence Limit | 3.41 |
| SIR: Lower Confidence Limit | .83 |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether DSI Seaford's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 76 |
| Transfusion Rate in facility | 8.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 43.4 |
| Transfusion Rate: Lower Confidence Limit | 2.2 |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at DSI Seaford lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 410 |
| Mortality Rate in facility | 16.6 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 21.3 |
| Mortality Rate: Lower Confidence Limit | 12.7 |
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago
News Archive
Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.
Researchers from the Institute of Psychiatry at King's College London have identified a molecule that could be targeted to treat the cognitive impairment in people with Down syndrome.
French researchers have found a way to identify quickly the 5-10% of patients in whom the commonly used painkiller, tramadol, does not work effectively. A simple blood test can produce a result within a few hours, enabling doctors to switch a non-responding patient on to another painkiller, such as morphine, which will be able to work in these patients.
Waters Corporation reported fourth quarter 2010 sales of $484 million, an increase of 13% from sales of $429 million in the fourth quarter of 2009. In the quarter, foreign currency translation was about neutral to sales growth. On a GAAP basis, earnings per diluted share (E.P.S.) for the fourth quarter were $1.36 compared to $1.08 for the fourth quarter of 2009.
› Verified 1 days ago